Mesothelin-Targeting T Cells Bearing a Novel T Cell Receptor Fusion Construct (TRuC) Exhibit Potent Antitumor Efficacy against Solid Tumors

Researchers reported that mesothelin-specific TRuC-T cells potently killed MSLN+ tumor cells in vitro and efficiently eradicated MSLN+ mesothelioma, lung, and ovarian cancers in xenograft mouse tumor models.